Möchten Sie immer auf dem neuesten Stand bleiben?

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel...

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim...

Alumis Announces Pricing of Upsized Public Offering of Common Stock

LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for...

Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market...

COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech...

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated...

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026